Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma
Open Access
- 1 January 2018
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 11, 4047-4050
Abstract
To date, there is no standard third-line therapy fbr EGFR- and ALK-negative lung squamous cell carcinoma (SCC). Apatinib, an oral small-molecule VEGFR-2 inhibitor, has shown good therapeutic effect and safety in chemotherapy-refractory gastric cancer, but its efficacy in lung SCC is not determined. In this report, we present a 69-year-old Chinese man with locally advanced EGFR- and ALK-negative lung SCC, who received apatinib after failure of 2 treatment regimens. After 4 months of apatinib therapy, chest computed tomography scan showed a large cavity in the lung tumor, while there was minimal change in tumor size. The patient had quite a long progression-free survival time of over 17 months and tolerated apatinib very well. Apatinib provides an additional option for salvage treatment of lung SCC without driver gene mutations, but further large-scale clinical studies are still warranted.Keywords
This publication has 17 references indexed in Scilit:
- Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2017
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal JunctionJournal of Clinical Oncology, 2016
- U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based ChemotherapyThe Oncologist, 2015
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- Apatinib for the treatment of gastric cancerExpert Opinion on Pharmacotherapy, 2014
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialThe Lancet, 2014
- Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II TrialJournal of Clinical Oncology, 2013
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivoCancer Science, 2011
- FDA Drug Approval Summary: Bevacizumab (Avastin®) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell Lung CancerThe Oncologist, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006